STOCK TITAN

Neumora (NASDAQ: NMRA) director gets 80,000 stock options at $1.86

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Neumora Therapeutics director Matthew K. Fust received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting after that date. Following this compensation award, Fust holds 80,000 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Fust Matthew K
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 80,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 80,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Stock options granted 80,000 options Grant of Stock Option (Right to Buy) to director
Exercise price $1.86 per share Conversion or exercise price of granted options
Expiration date May 26, 2036 Option expiration for 80,000-share grant
Shares underlying options 80,000 shares Underlying Common Stock tied to granted options
Holdings after transaction 80,000 derivative securities Total stock options held directly after grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 1.8600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Meeting financial
"immediately prior to the next Annual Meeting following May 27, 2026"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
vest financial
"100% of the shares subject to the option vest on the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fust Matthew K

(Last)(First)(Middle)
C/O NEUMORA THERAPEUTICS, INC.
260 ARSENAL PLACE, SUITE 1

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.8605/27/2026A80,000 (1)05/26/2036Common Stock80,000$080,000D
Explanation of Responses:
1. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
/s/ Michael Milligan, as Attorney-in-Fact for Matthew K. Fust05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neumora (NMRA) director Matthew K. Fust report?

Matthew K. Fust reported receiving a grant of stock options for 80,000 shares of Neumora Common Stock. The options are a compensation award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the Neumora (NMRA) stock options granted to Matthew Fust?

The granted stock options have an exercise price of $1.86 per share. This means Fust can buy up to 80,000 Neumora Common Stock shares at $1.86, regardless of the market price, once the options are vested and before they expire.

When do Matthew Fust’s Neumora (NMRA) stock options vest?

All 80,000 stock options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting after that date. Vesting must occur before the options become exercisable for Neumora shares.

When do the Neumora (NMRA) stock options granted to Matthew Fust expire?

The stock options granted to Matthew Fust expire on May 26, 2036. After this expiration date, any unexercised portion of the 80,000 options can no longer be used to purchase Neumora Common Stock at the $1.86 exercise price.

Is Matthew Fust’s Neumora (NMRA) Form 4 transaction an open-market buy or sale?

The Form 4 shows a grant of stock options as a compensation award, not an open-market trade. The transaction is coded as an acquisition (A) of derivative securities, giving Fust the right to buy shares later instead of immediately purchasing or selling stock.

How many Neumora (NMRA) derivative securities does Matthew Fust hold after this Form 4 transaction?

After this transaction, Matthew Fust holds 80,000 derivative securities in the form of stock options. These options each relate to one share of Neumora Common Stock and are held directly, subject to the vesting schedule and the May 26, 2036 expiration date.